Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

Alphatec (NASDAQ:ATEC - Get Rating) had its target price dropped by The Goldman Sachs Group from $11.00 to $9.50 in a report released on Monday, Stock Target Advisor reports. The firm presently has a "neutral" rating on the medical technology company's stock. The Goldman Sachs Group's price objective would indicate a potential upside of 16.42% from the stock's current price.

Several other research firms have also recently weighed in on ATEC. Lake Street Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Alphatec in a research note on Friday, July 15th. Needham & Company LLC reduced their target price on shares of Alphatec from $15.00 to $13.00 and set a "buy" rating for the company in a research note on Thursday, May 26th. Finally, HC Wainwright increased their target price on shares of Alphatec from $19.00 to $20.00 in a research note on Friday, May 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $15.08.Alphatec Stock Performance

ATEC stock traded down $0.02 during mid-day trading on Monday, reaching $8.16. 4,086 shares of the stock traded hands, compared to its average volume of 698,038. The company has a quick ratio of 1.76, a current ratio of 2.62 and a debt-to-equity ratio of 7.78. Alphatec has a 52 week low of $5.73 and a 52 week high of $15.31. The business has a 50-day moving average of $7.13 and a two-hundred day moving average of $9.32. The firm has a market capitalization of $830.35 million, a PE ratio of -5.05 and a beta of 1.62.

Alphatec (NASDAQ:ATEC - Get Rating) last released its earnings results on Thursday, May 5th. The medical technology company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.14). Alphatec had a negative net margin of 55.97% and a negative return on equity of 210.22%. The company had revenue of $70.93 million during the quarter, compared to the consensus estimate of $67.72 million. As a group, equities analysts predict that Alphatec will post -1.4 EPS for the current fiscal year. Insider Activity at Alphatec

In related news, Director James L. L Tullis acquired 7,500 shares of the firm's stock in a transaction that occurred on Wednesday, June 15th. The stock was acquired at an average price of $6.76 per share, for a total transaction of $50,700.00. Following the completion of the acquisition, the director now owns 187,558 shares of the company's stock, valued at approximately $1,267,892.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Patrick Miles sold 100,000 shares of Alphatec stock in a transaction dated Wednesday, May 18th. The shares were sold at an average price of $8.34, for a total value of $834,000.00. Following the completion of the transaction, the chief executive officer now owns 5,858,634 shares in the company, valued at $48,861,007.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James L. L. Tullis bought 7,500 shares of Alphatec stock in a transaction dated Wednesday, June 15th. The stock was acquired at an average price of $6.76 per share, with a total value of $50,700.00. Following the purchase, the director now directly owns 187,558 shares of the company's stock, valued at $1,267,892.08. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 79,700 shares of company stock valued at $563,300 and have sold 300,000 shares valued at $2,339,500. 33.93% of the stock is owned by insiders. Hedge Funds Weigh In On Alphatec

Several large investors have recently modified their holdings of the business. First Light Asset Management LLC grew its stake in Alphatec by 16.9% during the first quarter. First Light Asset Management LLC now owns 2,718,120 shares of the medical technology company's stock valued at $31,258,000 after acquiring an additional 392,635 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in Alphatec by 1,344.0% during the fourth quarter. Envestnet Asset Management Inc. now owns 374,788 shares of the medical technology company's stock valued at $4,284,000 after purchasing an additional 348,834 shares during the last quarter. King Luther Capital Management Corp lifted its holdings in shares of Alphatec by 44.6% in the 1st quarter. King Luther Capital Management Corp now owns 1,014,885 shares of the medical technology company's stock worth $11,671,000 after acquiring an additional 313,073 shares during the last quarter. Waypoint Capital Advisors LLC bought a new stake in shares of Alphatec in the 1st quarter worth approximately $3,739,000. Finally, Pier Capital LLC lifted its holdings in shares of Alphatec by 55.0% in the 1st quarter. Pier Capital LLC now owns 617,812 shares of the medical technology company's stock worth $7,105,000 after acquiring an additional 219,157 shares during the last quarter. Hedge funds and other institutional investors own 53.52% of the company's stock. Alphatec Company Profile (Get Rating)

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement.Further ReadingGet a free copy of the StockNews.com research report on Alphatec (ATEC)Two Appealing Biotech Stocks for Two Distinct investorsIs Tyson Foods A Buy On Post-Earnings Weakness? Is DoorDash Ready To Sprint Higher? Electric Vehicles Can Drive Alcoa Stock HigherCan Airbnb Still Thrive in a Recession?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Alphatec, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alphatec wasn't on the list.

While Alphatec currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

What investors can learn from studying the past, as well as offering some ideas about asset classes with future potential.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.